通过巨细胞传递CD52信号的Siglec-G代表了癌症免疫治疗的治疗标

Xueting Qin1,2, Yixin Chang2, Yuanyuan Qiu3

  • 1School of Medicine, Nankai University, Tianjin, China.

NPJ breast cancer
|January 24, 2026
PubMed
概括

研究人员确定CD52是三阴性乳腺癌 (TNBC) 中的一种新的"不要吃我"信号. 阻止CD52可恢复巨细胞对癌细胞的清除,为TNBC提供一种新的免疫治疗策略.

相关概念视频

The Representativeness Heuristic02:13

The Representativeness Heuristic

The representative heuristic describes a biased way of thinking, in which you unintentionally stereotype someone or something. For example, you may assume that your professors spend their free time reading books and engaging in intellectual conversation, because the idea of them spending their time playing volleyball or visiting an amusement park does not fit in with your stereotypes of professors.
16.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.7K